Xeris Biopharma Holdings (XERS) Cost of Revenue (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Cost of Revenue came in at $10.6 million in Q1 2026, up 21.15% YoY from $8.7 million in Q1 2025, and down 3.41% on a QoQ basis from $10.9 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Cost of Revenue (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Cost of Revenue data on file, last reported at $10.6 million in Q1 2026.
- Quarterly Cost of Revenue rose 21.15% year-over-year to $10.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.4 million (up 12.19% YoY) and the FY2025 annual result came in at $42.6 million, up 15.58% from the prior year.
- Cost of Revenue declined to $10.6 million in Q1 2026, from $10.9 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $13.6 million in Q3 2024 to a low of $4.8 million in Q2 2022.
- A 5-year average of $8.3 million and a median of $7.8 million in 2024 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2022 — Cost of Revenue soared 243.54% — and 2025, when it retreated 19.11%.
- Tracing XERS's Cost of Revenue over 5 years: stood at $6.3 million in 2022, then advanced by 20.33% to $7.6 million in 2023, then gained by 25.2% to $9.5 million in 2024, then rose by 15.5% to $10.9 million in 2025, then fell by 3.41% to $10.6 million in 2026.
- The last three Cost of Revenue figures came in at $10.6 million (Q1 2026), $10.9 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.50 Bn | 1.38 Bn | 79.59 Mn | 12.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.51 Mn |
| Jun 30, 2026 | 12.51 Mn |
| Mar 31, 2026 | 10.57 Mn |
| Mar 31, 2026 | 10.57 Mn |
| Dec 31, 2025 | 10.95 Mn |
| Dec 31, 2025 | 10.95 Mn |
| Sep 30, 2025 | 11.00 Mn |
| Sep 30, 2025 | 11.00 Mn |
| Jun 30, 2025 | 11.90 Mn |
| Jun 30, 2025 | 11.90 Mn |
| Mar 31, 2025 | 8.73 Mn |
| Mar 31, 2025 | 8.73 Mn |
| Dec 31, 2024 | 9.48 Mn |
| Dec 31, 2024 | 9.48 Mn |
| Sep 30, 2024 | 13.59 Mn |
| Sep 30, 2024 | 13.59 Mn |
| Jun 30, 2024 | 7.79 Mn |
| Jun 30, 2024 | 7.79 Mn |
| Mar 31, 2024 | 5.97 Mn |
| Mar 31, 2024 | 5.97 Mn |